isavuconazole and Central-Nervous-System-Fungal-Infections

isavuconazole has been researched along with Central-Nervous-System-Fungal-Infections* in 2 studies

Other Studies

2 other study(ies) available for isavuconazole and Central-Nervous-System-Fungal-Infections

Article	Year
Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. Medical mycology, 2020, Jun-01, Volume: 58, Issue:4 The incidence of invasive fungal diseases (IFDs) with central nervous system (CNS) involvement is increasing due to the rising numbers of immunocompromised individuals, such as patients receiving chemotherapy, transplantation procedures, or immune-modulating therapies. CNS IFDs cause significant morbidity and mortality, and treatments are complicated by difficulties in identifying fungal pathogens and delivering antifungal agents to the CNS. Isavuconazole is a novel triazole with broad-spectrum activity that has shown good blood-brain barrier penetration in animal models. We present a retrospective analysis of isavuconazole in the treatment of patients with CNS IFDs and who either participated in the phase III VITAL or SECURE clinical trials, or were included in a named-patient program. A total of 36 patients were identified, including 27 patients from the clinical trials. Of these patients, 47.2% had hematologic malignancies, while 13.9% had no identifiable underlying conditions. Mucorales, Aspergillus species, and Cryptococcus species accounted for 30.6%, 22.2%, and 13.9% of infections, respectively. The overall survival rate was 80.6% at day 42 and 69.4% at day 84, and at the end of treatment, a complete or partial clinical response was achieved in 58.3% of patients. Isavuconazole exhibited clinical activity in a variety of CNS IFDs. Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Central Nervous System Fungal Infections; Child; Child, Preschool; Clinical Trials, Phase III as Topic; Drug Resistance, Fungal; Female; Fungi; Humans; Invasive Fungal Infections; Male; Middle Aged; Nitriles; Pyridines; Retrospective Studies; Survival Analysis; Triazoles; Young Adult	2020
Isolated cerebral mucormycosis associated with intravenous drug use. Journal de mycologie medicale, 2020, Volume: 30, Issue:4 We present an uncommon case of isolated basal ganglia mucormycosis in a patient without any known cause of immunosuppression, but with a history of drug injection. The patient presented a good clinical and radiological response to antifungal treatment without aggressive surgical debridement (liposomal amphotericin B combined with isavuconazole for 4 weeks followed by isavuconazole as maintenance therapy for 10 months). Topics: Amphotericin B; Central Nervous System Fungal Infections; Cocaine; Cocaine-Related Disorders; Drug Therapy, Combination; Drug Users; Humans; Magnetic Resonance Imaging; Male; Marijuana Abuse; Middle Aged; Mucormycosis; Nitriles; Pyridines; Substance Abuse, Intravenous; Triazoles	2020

Article

Year

Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.

Medical mycology, 2020, Jun-01, Volume: 58, Issue:4

The incidence of invasive fungal diseases (IFDs) with central nervous system (CNS) involvement is increasing due to the rising numbers of immunocompromised individuals, such as patients receiving chemotherapy, transplantation procedures, or immune-modulating therapies. CNS IFDs cause significant morbidity and mortality, and treatments are complicated by difficulties in identifying fungal pathogens and delivering antifungal agents to the CNS. Isavuconazole is a novel triazole with broad-spectrum activity that has shown good blood-brain barrier penetration in animal models. We present a retrospective analysis of isavuconazole in the treatment of patients with CNS IFDs and who either participated in the phase III VITAL or SECURE clinical trials, or were included in a named-patient program. A total of 36 patients were identified, including 27 patients from the clinical trials. Of these patients, 47.2% had hematologic malignancies, while 13.9% had no identifiable underlying conditions. Mucorales, Aspergillus species, and Cryptococcus species accounted for 30.6%, 22.2%, and 13.9% of infections, respectively. The overall survival rate was 80.6% at day 42 and 69.4% at day 84, and at the end of treatment, a complete or partial clinical response was achieved in 58.3% of patients. Isavuconazole exhibited clinical activity in a variety of CNS IFDs.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Central Nervous System Fungal Infections; Child; Child, Preschool; Clinical Trials, Phase III as Topic; Drug Resistance, Fungal; Female; Fungi; Humans; Invasive Fungal Infections; Male; Middle Aged; Nitriles; Pyridines; Retrospective Studies; Survival Analysis; Triazoles; Young Adult

2020

Isolated cerebral mucormycosis associated with intravenous drug use.

Journal de mycologie medicale, 2020, Volume: 30, Issue:4

We present an uncommon case of isolated basal ganglia mucormycosis in a patient without any known cause of immunosuppression, but with a history of drug injection. The patient presented a good clinical and radiological response to antifungal treatment without aggressive surgical debridement (liposomal amphotericin B combined with isavuconazole for 4 weeks followed by isavuconazole as maintenance therapy for 10 months).

Topics: Amphotericin B; Central Nervous System Fungal Infections; Cocaine; Cocaine-Related Disorders; Drug Therapy, Combination; Drug Users; Humans; Magnetic Resonance Imaging; Male; Marijuana Abuse; Middle Aged; Mucormycosis; Nitriles; Pyridines; Substance Abuse, Intravenous; Triazoles

2020